5 Best Debt Free Stocks to Buy Right Now

3. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

On March 24, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi (SNY) announced that Japan’s Ministry of Health, Labour and Welfare approved Dupixent for the treatment of adults with moderate-to-severe bullous pemphigoid. The approval is based on data from the LIBERTY-BP-ADEPT Phase 2/3 trial evaluating Dupixent in adults with the condition.

On March 19, 2026, Wells Fargo raised the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $825 from $800 and maintained an Equal Weight rating. Wells Fargo said new drugs and mechanisms such as CD20, BAFF/APRILs, and next generation complement inhibitors could expand the generalized Myasthenia Gravis market to $15B in the U.S. and $20B globally by 2036, more than tripling its size, and noted that Vertex Pharmaceuticals (VRTX), Amgen (AMGN), and Regeneron could be among the largest beneficiaries, with potential upside to current estimates.

Earlier in March, Barclays initiated coverage on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) with an Overweight rating and a $923 price target, saying the stock is “fundamentally mispricing” profits from Dupixent and highlighting pipeline opportunities, including Lynozyfic, along with indication expansion as an “underappreciated tailwind.”

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) develops and commercializes medicines across multiple therapeutic areas worldwide.